Trials have shown that granulocyte colony-stimulating factor (G-CSF) has the potential to reduce the duration of neutropenia, thereby preserving the therapeutic benefit of venetoclax by avoiding premature discontinuation. The gene discussed is CSF3; the disease is neutropenia.